RILPL1: A Potential Drug Target and Biomarker for Various Diseases

Target Name: RILPL1

NCBI ID: G353116

RILPL1

RILPL1: A Potential Drug Target and Biomarker for Various Diseases

RILP-like protein 1 (RILPL1) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. RILPL1 is a member of the RILP family of proteins, which are known for their role in regulating various cellular processes, including cell signaling, DNA replication, and stress responses. The identification of RILPL1 as a potential drug target and biomarker has significant implications for the development of new treatments for a variety of diseases.

Disease-related functions of RILPL1

RILPL1 is involved in various cellular processes that are crucial for maintaining cellular health and homeostasis. It has been shown to play a role in regulating cell signaling pathways, including the DNA replication pathway. RILPL1 has been shown to interact with various DNA replication factors, including DNAPK, which is a key regulator of DNA replication initiation.

In neurodegenerative diseases, RILPL1 has been shown to contribute to the pathogenesis of various diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These conditions are characterized by the progressive loss of brain cells and the presence of neurofibrillary tangles and other aberrant cellular structures.

In addition to its role in neurodegenerative diseases, RILPL1 has also been shown to be involved in cancer progression. Many studies have shown that RILPL1 is highly expressed in various types of cancer, including breast, lung, and ovarian cancers. It has also been shown to contribute to the development of resistance to chemotherapy in cancer cells.

Potential drug targets and biomarkers

The identification of RILPL1 as a potential drug target and biomarker has significant implications for the development of new treatments for various diseases. If approved, RILPL1 could be used as a target for small molecule inhibitors, monoclonal antibodies, or adoptive T cell therapy.

In addition to its potential as a drug target, RILPL1 has also been shown to be a potential biomarker for various diseases. Its expression has been shown to be associated with various diseases, including neurodegenerative diseases, cancer, and autoimmune disorders.

Conclusion

In conclusion, RILPL1 is a protein that has significant implications for the development of new treatments for various diseases. Its involvement in various cellular processes, including cell signaling, DNA replication, and stress responses makes it an attractive target for small molecule inhibitors, monoclonal antibodies, or adoptive T cell therapy. Its potential as a biomarker for neurodegenerative diseases and cancer further increases its potential as a drug target. Further research is needed to fully understand the role of RILPL1 in disease and to develop effective treatments.

Protein Name: Rab Interacting Lysosomal Protein Like 1

Functions: Plays a role in the regulation of cell shape and polarity (By similarity). Plays a role in cellular protein transport, including protein transport away from primary cilia (By similarity). Neuroprotective protein, which acts by sequestring GAPDH in the cytosol and prevent the apoptotic function of GAPDH in the nucleus (By similarity). Competes with SIAH1 for binding GAPDH (By similarity). Does not regulate lysosomal morphology and distribution (PubMed:14668488). Binds to RAB10 following LRRK2-mediated RAB10 phosphorylation which leads to inhibition of ciliogenesis (PubMed:30398148)

The "RILPL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RILPL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets